Celecoxib is a selective COX-2 inhibitor non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. Celecoxib is practically inslouble in GIT pH. Consequently, it suffers from low and variable bioavailability following oral administration of solutions (64-88%) and capsules (20-40%) In the present study, gastroretentive controlled release single-unit floating capsules of Celecoxib were designed and evaluated. Various grades of low and high viscosity polymers of HPMC 4000 and 15.000 cps and NaCMC were used for formulation of Celecoxib capsules.
INTRODUCTION
For the past three decades, oral controlled release dosage forms have been developed due to their important therapeutic advantages. By the introduction of a variety of controlled delivery systems, the inconvenience of conventional tablets or capsules that resulted in a transient overdose, followed by a long period of dosing was overcome. One of these delivery systems is the gastroretentive drug delivery systems (GRDDSs).
Besides being able to continually and sustainedly deliver drugs to the small intestinal absorption window, the improvements provided from GRDDSs include: achieving a greater and prolonged therapeutic effect and thus reducing the frequency of administration periods, providing a more effective treatment of local stomach disorders, and minimizing both lowertract inactivation of the drug and drug effects on the lower intestinal flora The above-mentioned approaches for gastrointestinal retention work by one or more of these mechanisms. The major challenge for a bioadhesive system is the high turnover rate of gastric mucus. Recent improvements in the field of size-increasing (swelling/expanding) drug delivery systems led to devices that caneasily be swallowed but rapidly increase in size once they reach the stomach, assuring prolonged gastric residence times. More importantly, their performance is independent of the filling state of the stomach and, after predetermined time intervals, they break into smaller pieces, guaranteeing their removal from the stomach. In contrast, the performance of low density, floating drug delivery systems is strongly dependent upon the filling state of the stomach (Streubel et al., 2006b). Various systems thus combining different gastroretentive mechanisms were developed to enhance gastroretention capabilities. Floating and bioadhesion to achieve retention have been combined in tablets consisting of blends of HPMC and Carbopol (Nur and Zhang, 2000) and tablets containing sotalol HCl, sodium carboxymethyl cellulose (as the bioadhesive polymer), HPC (as the matrix-forming polymer), and carbonate (as the gas generator) (Jiménez-Castellanos et al., 1994).
Effervescent tablets with bioadhesive capabilities for ciprofloxacin were made of sodium carboxymethyl cellulose, HPMC, polyacrylic acid, polymethacrylic acid, citric acid, and sodium bicarbonate to lengthen the stay in the absorption region A new sustained gastroretentive release delivery system was developed with floating (sodium bicarbonate), swellable (crospovidone and betacyclodextrin), and bioadhesive (psyllium husk and HPMC) properties of ofloxacin . A simple addition of sodium bicarbonate to the gel matrix-forming floating tablets made of HPMC and captopril was characterized by increased hydration volume and buoyancy (Jiménez-Martnez et al., 2008). Kollidon® SR (due to its low density) and sodium bicarbonate were added to compensate for the deficient floating properties of propranolol HCl in the preparation of directly compressible GRDDS (Strübing et al., 2008a, b).
Swellable, floating, and sustained release tablets developed by using a combination of hydrophilic polymer (HPMC), swelling agents (crospovidone, sodium starch glycolate, and croscarmelose sodium), and an effervescent substance (sodium bicarbonate) were found to show good swelling, drug release, and floating characteristics than CIFRAN OD® of which swellability of hydrophilic polymer was the main mechanism of gastroretention (Arza et al., 2009). In this preliminary study, it was found that hydrocolloid tablets made of PEO 8,000K had the largest swelling index, followed by hydroxyethyl cellulose (HEC), and the least for sodium carboxymethyl cellulose (NaCMC, 450 cps or 2500 cps). However, the floating ability of these three polymeric materials was in the following order, HEC >NaCMC> PEO 8,000K, with the last material sinking to the bottom. Since both swelling/expanding to a larger size and floating in gastric fluid could extend stomach retention, it was thought that simply incorporating NaCMC in the matrix of HEC might synergistically enhance gastroretentive ability.
GRDDS was designed to prolong gastric residence time and provide for enhanced low bioavailability of Losartan relative to an equal dose of an immediate-release formulation through development of a swellable and floatable GRDDS based on a combination of sodium carboxymethyl cellulose (NaCMC) in hydroxyethyl cellulose (HEC) 
Surface Adsorption
When poorly water-soluble drugs are administered in solid dosage forms, the dissolution rate is often considered as a rate-limiting factor in the absorption process. The rate of dissolution of these drugs depends upon the effective surface area and the energy state within the drug crystals (Shaker et al., 1992).Various techniques have been used to reduce particle size and, hence, increase surface area. These include freeze-drying (Chacon et al., 1999), spray drying (Sato et al., 1981), and preparation of solid dispersions and molecular dispersions with certain hydrophilic carriers (Abdel-Rhaman et al., 1989; Hong et al., 1998).
Adsorption of drugs onto surfaces of inert matrices has been widely employed to reduce particle size of the drug by increasing the effective surface area available for dissolution. The technique of surface adsorption was first reported by Monkhouse and Lach (Mankhouse and Lach 1972) . Florite® (porous calcium silicate, 2CaO 3SiO 2 , nH 2 O), which has a characteristic porous structure and very low density, has been used for the development of an intragastric floating and sustained-release preparation. The floating ability of Florite® results from the air trapped in the porous structure of calcium silicate (Yuassa, et al., 1996) .
Ad-Solubilization (Co-Adsorption)
The use of surface-active agents as effective solubilizing aids in solid dosage forms is limited by their physico-chemical properties, as the majority of water soluble surfactants exist as viscous liquids or waxy solids at ambient temperatures. For obvious reasons, such materials are generally not conductive to the formulation and manufacture of traditional pharmaceutical tablets and capsules (Ruddy et al., 1999) .
Surface-active agents may be adsorbed at solid hydrophilic interfaces forming various types of aggregates such as admicelles or bilayers depending upon the characteristics of the solid surface and surfactant, as well as, the physico-chemical conditions of the system in terms of pH and ionic strength. These surfactant aggregates may incorporate drug molecules which otherwise would not adsorb spontaneously onto the solid surface (Cherkaoui et al.,  2000) .
This phenomenon has been termed co-adsorption (Monticone and Treiner 1995) or ad-solubilization to emphasize that it concerns surfactants adsorbed at solid-liquid interfaces. In ad-solubilization, drug molecules are incorporated by a mechanism very similar to both ion-exchange and solubilization processes as it occurs in the classical micellar solutions (Cherkaoui et al., 2000). However, as the surfactant concentration is increased above the critical micelle concentration (cmc) and the solid surface becomes saturated, free micelles must form. Therefore, equilibrium will be established between the fraction of the solute adsorbed at the solid interface and the fraction that is solubilized in the free micelles (Monticone and Treiner 1995).
Many investigations have been made particular emphasis on the importance of surface modification by surfactants for the incorporation of various drugs. For example, using other solid substrates such as alumina, acrylic matrices, albumin, and cyanoacrylate nanoparticles In an attempt to enhance the dissolution rate of Celecoxib, adosrbates and coadsorbates of the drug were prepared using different adsorbents e.g., Aerosil and Florite® in the presence of polysorbate 80, then formulated in floated capsules to investigate the effect of these additives on the floating behavior and drug release.
Materials:
Celecoxib was obtained as a gift from Sedico Company (Egypt), Hydroxypropyl methyl cellulose, HPMC 4000cps and Sodium carboxymethly cellulose, NaCMC were supplied from Aldrich Chemicals Co., USA, Anhydrous lactose, Shefield chemical, N.J., USA, Magnesium stearate and sodium bicarbonate were obtained from El-Nasr Pharmaceutical Chemicals Co., Egypt, Transparent hard gelatin capsules (size 000), were kindly supplied by T3A Pharmaceutical Company, Assiut (Egypt), Porous calcium silicate (Florite®) was obtained from Tokuyama soda co, Japan, Colloidal silicon dioxide (Aerosil 200), (Degussa Frankfurt, Germany), Polysorbate (Tween 80) was purchased from BDH Chemicals Ltd., Poole (England).
Equipments:
Differential Scanning Calorimetry, DSC-50 and FTIR-Spectrophotometer, IR-470 (Shimadzu, Japan), Single Punch Tablet Machine, Korsch-Berlin, EK/0, Franckfort Celecoxib powder (25 mg) was used for the preparation of floating capsules. HPMC 4000, HPMC 15000, sodium bicarbonate, and CMC sodium were used in different concentrations. Magnesium stearate was added in the concentration of 1% w/w as a lubricant, while anhydrous lactose was used as a diluent to obtain the desired weight of each capsule.
The calculated amount of each ingredient was mixed in a suitable dish till a homogenous mixture was obtained. The powder blend was then placed in a horizontal plate. Hard gelatin capsules were filled manually by bunching the capsule body against the powder sheet. The weight of each filled capsule was adjusted to the required weight 150 mg. The different prepared formulae of Celecoxib floating capsules were taken the symbols of FC1 -FC12 as it was shown in table (1). 
1.2-Evaluation of the Prepared Conventional Celecoxib Floating Capsules
The prepared Celecoxib capsules were evaluated for the uniformity of weight and drug content.
1.2.1-Uniformity of weight
Twenty capsules were weighed individually. The contents of each capsule were removed and the empty shells were weighed individually again. The net weight of the content of each capsule was calculated by subtracting the weight of the shell from the respective gross weight. The average weight was determined according to the USP XXV.
1.2.2-Uniformity of drug content
Random samples of 10 capsules from each batch were tested for the uniformity of drug content. The contents of capsules were removed by opening each capsule individually and the drug in each was extracted with 100 ml of methanol. The solution was filtered, suitably diluted with 0.1N HCl and assay spectrophotometrically at λ the maximum wave length of 252 nm for Celecoxib content using the suitable blank.
1.2.3-Floating Behavior of the Prepared Conventional Celecoxib Floating Capsules
The USP dissolution apparatus (USP apparatus II) was used in this test. The glass vessels of the apparatus were filled with 500 ml of 0.1 N. HCl (simulated gastric fluid without enzymes) maintained at 37± 0.5°C and rotated at 100 rpm.
The buoyancy lag time and the duration of buoyancy of the prepared Celecoxib floating capsules were determined. The time taken by each formula to start floating (floating lag time) was determined. The time for each dosage form to remain buoyant (floated) over the solution was determined and taken as the floating time (Ingani et al., 1987; Yang, 1999).
1.2.4-In-Vitro Drug Release Study from the Prepared Conventional Floating Capsules
The release rates of Celecoxib from the prepared floating capsules were determined using USP apparatus II (paddle-type) rotated at 100 rpm. The dissolution medium consisted of 500 ml (pH 1.2) maintained at 37± 0.5°C.
One capsule from each formula (containing 25 mg Celecoxib) was placed in each vessel and subjected to the dissolution test.
Samples (5ml of aliquot) were withdrawn with volumetric pipette at predetermined time intervals of 15, 30, 60, 90, 120, 150, 180, 240, 300, 360, 240 and 480 minutes and filtered off. The medium was replenished immediately with the same volume of fresh dissolution medium maintained at the same temperature. Samples were analyzed by using UV spectrophotometer for their Celecoxib content at λ max = 252 nm against the blank ( 
2-Celecoxib Mixtures 2.1-Preparation of Celecoxib Physical Mixtures
Physical mixtures of Celecoxib with either Aerosil 200 or Florite® at a ratio of (1:1, 1:3 and 1:5 w/w drug: adsorbent) were prepared by gentle and smooth mixing of the required amount of the drug and the adsorbent using a glass pestle and a mortar. The prepared mixtures were sieved to obtain a particle size range of 125-250 µm and then stored in a desiccator over calcium chloride till investigation.
2.2-Preparation Of Celecoxib Ground Mixtures
Ground mixtures of Celecoxib with Florite® or Aerosil 200 at 1:1, 1:3 and 1:5 w/w drug: adsorbent ratios were prepared by grinding the physical mixtures of the drug with each adsorbent in a vibrating uniball mill for 15 min. The prepared mixtures were sieved to obtain a particle size range of 125-250 µm and then stored in a desiccator over calcium chloride till use.
2.3-Preparation of Celecoxib Loaded Mixtures by Solvent Deposition Method
Initially, Florite® and Aerosil 200 were activated in a vacuum drier at 110 ºC and 70 ºC for 3 and 24 hours respectively, after that the materials were kept at a room temperature in a desiccator over calcium chloride till investigation. Loaded mixtures of Celecoxib with either Florite® or Aerosil 200 were prepared by solvent deposition method of 1:1, 1:3 and 1:5 w/w drug: adsorbent ratios. Accordingly, the required amount of Celecoxib was dissolved in methanol and the required amount of the adsorbent was added with stirring for 30 min then the solvent was evaporated in vacuum at 40 ºC till constant weight was obtained. A particle size range of 125-250 µm was selected prepared and then stored in a desiccator over calcium chloride till use.
2.4-Preparation of Celecoxib Co-adsorbates
Celecoxib solubilized in the investigated surfactant solutions was adsorbed onto surface of Florite® or Aerosil 200 using solvent deposition method. The calculated amount of each adsorbent was added to methanolic solution of drug and surfactant to obtain the desired weight ratios of drug to surfactant to adsorbent of (1:1:5, 1:3:5 and 1:5:5 w/w drug: surfactant: carrier). The solution was treated using the same procedure described under preparation of adsorbates.
2.5-Compatibility and Characterization Study of Celecoxib Adsorbates 2.5.1-Infrared Spectroscopy:
Samples (1-2 mg) of drug alone, physical mixture, groung mixture, adsorbate and coadsorbate were mixed with potassium bromide (IR grade), compressed into discs in the compressor unit under vacuum, and scanned from 4000 -800 cm -1 with an empty pellet holder as a reference.
2.5.2-Differential Scanning Calorimetric Studies
Samples (3-6 mg) were weighed and hermetically sealed in flat-bottomed aluminum pans. Samples of drug alone, excipients alone as well as their corresponding physical mixtures (1;1 w/w) prepared by simple blending and prefect mixing on a clean waxy paper were subjected DSC investigation. The DSC thermograms were obtained over a temperature range of 30 -250 ºC with a thermal analyzer equipped with advanced computer software program at a scanning rate of 10 ºC / min and N 2 purge of 40 ml / min. the instrument was calibrated with indium as a standard.
2.5.3-Powder X-Ray Diffraction (P-XRD)
The X-ray diffractograms for different samples with particle size range of (250-125) μm were determined using the Philips 1710 automated diffractometer. The relation was provided by Cukά radiation operating at 40 KV and current of 30 mA Kά = 1.5418. The system was calibrated using standard polycrystalline silicon. The differential patterns were achieved using continuous scan mode with 2θ ranging from 4˚ to 60˚. The obtained output data were represented by 2θ, dA intensities and determined via the microprocessor of the PW/1710.
2.5.4-Determination of Drug Content of the Prepared Celecoxib Adsorbates
An accurately weighed sample of the prepared Celecoxib adsorbates equivalent to 25mg of the drug was added to 100 ml volumetric flask, then dissolved in minimum amount of alcohol and complete the volume to 100 ml by HCl buffer (pH 1.2). After suitable dilution, Celecoxib content was determined spectrophotometrically at λ max 252 nm. Only those samples containing 100 ± 5% of the claimed amounts of Celecoxib were considered for further studies.
2.5.5-In-Vitro Dissolution Studies of the Prepared Celecoxib Adsorbates
Dissolution experiments were carried out in triplicate with USP apparatus ΙІ dissolution using paddle at a rotation speed of 100 rpm. Powdered samples of each preparation equivalent to 25 mg of Celecoxib were added to the dissolution medium (900 ml of pH 1.2) kept at 37±0.5ºC. At appropriate time intervals, 5 ml of the solution was withdrawn using cotton plug from the dissolution medium and replaced with an equal volume of the fresh dissolution medium equilibrated at 37ºC. The samples were assayed spectrophotometrically at λ max 252 nm. It was found that none of the additives used interfered with the spectrophotometric assay of the drug in the dilution range used. The mean of three determinations was considered.
-Celecoxib Adsorbates Floating Capsules 3.1 -Preparation of Celecoxib Adsorbates Floating Capsules
Celecoxib powder or its coadsorbate with polysorbate 80 onto Florite®, mixed with different concentrations of HPMC 4000 (12.5, 25, and 50 mg) were used for the preparation of floating capsule dosage forms. Sodium bicarbonate was used in a concentration of 10.5 mg w/w of capsule, while magnesium stearate was added in a concentration of 1% w/w of capsule. Anhydrous lactose was used a filler to obtain the desired weight of capsules. Floating capsule dosage forms were prepared by manual filling. The different formulae of floating capsule dosage forms of Celecoxib show the amount of each ingredient in mg. The prepared formulae of floating capsule dosage forms are given the symbols of C1-C6, see table (2). The calculated amounts of each ingredient were mixed in a large dish till a homogenous mixture was obtained. The powder blend was then placed on a horizontal plate. Hard gelatin capsules No. 000 were filled manually by bunching the capsule body against the powder sheet.
The weight of each filled capsule was adjusted to the required weight (350 mg). Different formulae of floating capsule dosage forms of Celecoxib show the amount of each ingredient in mg. The prepared formulae of floating capsule dosage forms are given the symbols of C1-C6.
3.2-Evaluation and Charaterization of Celecoxib Adsorbates Capsules 3.2.1-Floating Time of the Prepared Celecoxib Adsorbates Capsules
The prepared floating capsules of Celecoxib adsorbates were evaluated as previously described.
3.2.2-In-Vitro Drug Release Study of Celecoxib from Adsorbates Floating Capsules
The USP dissolution apparatus (USP apparatus II) was used in this test. The glass vessels of the apparatus were filled with 500 ml of 0.1 NHCl buffer pH 1.2 (simulated gastric fluid without enzymes) and all maintained at 37±0.5°C and rotated at 100 rpm. The release rates of Celecoxib from the prepared floating capsules and tablets were determined using USP rotating paddle method (USP apparatus II). One capsule or tablet from each formula (containig 25 mg of Celecoxib) was placed in each vessel and subjected to the dissolution test.
Each dissolution test was composed of three test samples and a blank solution that was running hand in hand with the test experiments. At specified time intervals, 5 ml samples were withdrawn from the dissolution media and filtered off. The UV absorbance of the drug was measured at λ max = 252 nm against the obtained blank. The dissolution volume was kept constant over the dissolution time. Therefore, at each time interval and after sample withdrawal, the volume was completed immediately using the dissolution medium preheated to 37°C. The release results were cumulatively corrected for the withdrawn samples.
The mean and standard deviation (of three results) were calculated for each time point and the final results were subjected to kinetic evaluation. Table ( 3) showed the mean weight and the mean drug content of the prepared Celecoxib capsules. The results showed that all the prepared capsules are uniform in weight according to USP XXV limits. The percent of the total drug content of the prepared capsules was in the range of 99.75 ± 0.05 to 100.7 ± 0.14. These values indicate that all the prepared capsules are in accordance with USP XXV requirements (USP XXV, 25 th ed., 2002).. 
RESULTS AND DISCUSSION

Conventional Celecoxib Floating Capsules 1.1-Evaluation of the Prepared Conventional Celecoxib Floating Capsules
1.2-Floating behavior of Conventional Celecoxib floating capsules
Table (4) showed the floating times and behaviors of the different prepared Celecoxib floating capsules (FC 1 -FC 12 ) in dissolution medium of pH 1.2. The floating time is taken as the period of time during which the capsule remains floating on the gastric fluid. After the hard gelatin capsule shell dissolved, the capsule contents adhered together forming a single unit that continued to float and swell gradually. During this time, Celecoxib diffused through the coadhered matrix to be released into the dissolution medium. All the prepared formulae of Celecoxib capsules floated immediately upon contact with the release medium, showing no lag times in floating behavior because the low density is provided from the beginning of the experiment (t = 0 min).
Celecoxib floating capsules (formulae FC 1 -FC 3 ) containing different concentrations of HPMC 4000 and 3% sodium bicarbonate using anhydrous lactose as a filler did not maintain their physical integrity for the desired period (8 hours) of time (Table 4) . Hence, an attempt was carried out in order to increase the physical integrity of the capsules using HPMC 15000.
Extended floating time (8 hours) is achieved for Celecoxib floating capsules (formulae FC 4 -FC 6 ) because the contents of capsules did not rapture but retained their definite shapes while floating. This may be due to the air entrapped within the HPMC 15000 matrix, which is only slowly removed from the system upon contact with the release medium.
Table (4) illustrates the effect of increasing the concentration of sodium bicarbonate (0%, 7%, and 10% w/w) on the floating times and behaviors of Celecoxib floating capsule containing 20% w/w of mg HPMC 15000 and anhydrous lactose as a filler. Celecoxib floating capsule (Formula FC 10 without sodium bicarbonate) did not maintain its physical integrity over one hour and the content of the capsule dispersed into smaller floating fragments. This may be attributed to the absence of the gas generating agent which acts to keep the dosage form buoyant on the dissolution medium. While formulae FC 11 and FC 12 (containing 7% and 10% w/w sodium bicarbonate, respectively) gave excellent floating behavior and were capable of maintaining their physical integrity throughout the whole dissolution test (8 hours). They swelled gradually and remained buoyant on the surface of the dissolution medium. In such systems, sodium bicarbonate reacts with the gastric hydrochloric acid to give carbon dioxide retained bubbles which cause floating of the capsule on the surface of the gastric content.
The effect of different concentration of NaCMC (10, 20, 30% w/w) in formulae (Fc 7 -Fc 9 ) respectively on the floating time and behaviors is shown in table (4). It was found that the solution slightly turbid because of the swelled matrix did not maintain integrity over 1.5 hr. The solution was clear because of the content of capsule did not rupture where is the absorption of water caused the capsule increase in the size and take the shape of gelatinous mass structure FC 7 -FC 9 Immediate 1.5 hour The solution was slightly turbid because of the swelled matrix did not maintain integrity over 1.5 hour FC 10 Immediate 1 hours Over the floating time stated the swelled matrix did not maintain its integrity. Furthermore, the content of the capsule dispersed however, some fragments of the hydrogel remained floating.
FC 11 & FC 12
Immediate All the dissolution period (8 hours)
During floating time it was observed that the content of the capsule did not rapture but still retained its shape. Also, the increase in the size of the capsule possibly attributed to the absorption of water causing the formation of gelatinous mass structure. Table ( 5) and Figure (1 A) showed the effect of different concentrations of HPMC 4000 on the release of Celecoxib from floating capsules (FC 1 -FC 3 ) containing anhydrous lactose as a filler and 3% w/w sodium bicarbonate as gas-generating agent at pH 1.2. It was found that by increasing the concentration of HPMC 4000 (from 10-30 w/w), decreased in the release rate of the drug from 42.25 to 37.28% after 480 min. Figure (1 B) show the effect of different concentrations of HPMC 15000 on the release of Celecoxib from floating capsules (FC 4 -FC 6 ) containing anhydrous lactose as a filler and 3% w/w sodium bicarbonate at pH 1.2. Celecoxib floating capsule containing different concentration of HPMC 15000 gave slowest release rate of the drug among the investigated floating capsules after the same time. Furthermore, increasing the amounts added of HPMC 15000 led to lower percentage of Celecoxib released from the floating capsules. Cumulative drug released from formulae FC 4 , FC 5 , and FC 6 after 480 min was found to be 31.24%, 28.82% and 25.01% respectively.
1.3-In-Vitro Drug Release Study from the Prepared Conventional Floating Capsules
Generally it was found that the release of Celecoxib from HPMC 4000 treated formulations was higher compared with those obtained from HPMC 15000 treated formulations. This can probably be attributed to the different diffusion and swelling behavior in/of these polymers. With increasing the molecular weight, the degree of entanglement of the polymer chain increases. Thus, the mobility of the macromolecules in the fluffy swollen systems decreases. According to the free volume theory of diffusion, the probability for a diffusing molecule to jump from one cavity into another, hence, decreases (Fan and Singh 1989). This leads to decreased drug diffusion coefficients and decreased drug release rates with increasing the molecular weights.
Table (5) and Figure (1 C) showed the effect of different concentration of sodium CMC as a swelling matrix on the release of Celecoxib from floating capsules (FC 7 -FC 9 ) containing anhydrous lactose as a filler and 3% w/w sodium bicarbonate at pH 1.2. Similar release rates of the drug were obtained form Celecoxib floating capsules containing different concentration rate of NaCMC (Fc 7 -Fc 9 ) with capsules containing HPMC 4000 (FC 1 -FC 3 ) using the same filler and gas generating agent.
The effect of different concentrations (0, 7, 10% w/w) of sodium bicarbonate (FC 10 -FC 12 ) on dissolution profile of Celecoxib from floating capsules was presented in Figure (1 D) and Table (4). The absence and/or altering the sodium bicarbonate concentrations did not affect the percentage of Celecoxib released from formulations (FC 10 -FC 12 ). Where that FC 10 , FC 11 and FC 12 showed 28.05%, 27.91% and 28.88% released of Celecoxib from floating capsules formulations, respectively, this might be attributed to the high viscosity of HPMC 15000 as described above. 
1.4-Investigation of Celecoxib release kinetics from the prepared capsules
In order to explore the mechanism of drug release from such systems, the experimental data of Celecoxib release were subjected to kinetic treatment. Different kinetic models were applied to interpret the release rate of the drug from the prepared floating capsules. The data were treated by linear regression analysis according to zero, first-order kinetics, and simplified Higuchi diffusion model .The obtained date for these formulae of Celecoxib floating capsules were in agreement with the work done by Ingani et al.
, (1987) & Gerogiannis et al., (1993).
Table (6) showed a comparison between the calculated correlation coefficient for the in-vitro release of Celecoxib floating capsules. According to the obtained results, drug release from the capsules can be described by different kinetic models (zero, first or Higuchi diffusion model) through the highest calculated correlation coefficient. 
2-Celecoxib Adsorbates and Co-adsorbate
Adsorbates and co-adsorbates of Celecoxib were formulated using HPMC 4000, as it gave the higher drug release from the floating capsules among the tested cellulosic polymers. Formulation of adsorbates and co-adsorbates was aimed to increase the release of drug from the floating dosage form beside prolongation of the floating time of the capsules in gastric medium.
2.1-Compatibility Study of Celecoxib with Adsorbates ingredients 2.1.1-Infrared Spectroscopy
In an attempt to elucidate the possible physical interactions of the different prepared systems, infrared absorption spectra were carried out. Figure ( 2) showed the IR spectra of pure Celecoxib, Florite® alone, its physical mixture, ground mixture and adsorbate as well as co-adsorbate systems. Curve A shows the IR spectrum of Celecoxib alone. Celecoxib has the following IR absorption bands at 3340, 3233 cm -1 for the NH 2 -group, 1103 cm -1 due to SO 2 bending, 1560 cm -1 corresponding to SO 2 stretching vibration and at 1347 cm -1 is assigned to CH 3 bending and at 3099 Cm -1 stretching vibration. The IR spectrum of Florite® alone is characterized by absence of any characteristic infrared absorption bands due to its inorganic nature (Trace B, Figure 2 ). The IR spectra of Celecoxib/ Florite® physical, ground and adsorbate mixtures (Traces C, D, E, Figure 2) show all the characteristic IR bands of Celecoxib but they are reduced in their intensities due to the higher ratio of Florite® in these prepared systems. The amino group (-NH 2 ), of the drug in their physical, ground and adsorbate mixtures with Florite® was shifted from 3450 cm -1 to 3420 cm -1 , 3410 cm -1 and 3415 cm -1 ;respectively. This can be attributed to the interaction of Celecoxib with Florite®.
The IR absorption spectrum of co-adsorbates of Celecoxib with polysorbate 80 onto the surface of Florite® in a ratio of (1:3:5 w/w) is presented in (Figure 2 , Trace F). It is clear that the major characteristic bands of the drug in its co-adsorbate are still present but with minor change and reduced in their intensities compared to plain drug. The amino group (-NH 2 ) of the drug in its coadsorbate was broad and shifted from 3450 cm -1 to 3405 cm -1 , this may be attributed to the interaction of the drug with Florite®.
It can be postulated that these molecular interactions involve weak bonds formation, e.g., hydrogen bonding or Vander Waal forces may be contributed in this interaction. A-Drug alone. B-Florite® alone. C-Physical mixture of (1:5w/w drug: Florite® ratio). D-Ground mixture of (1:5w/w drug: Florite® ratio). E-Adsorbates (1:5w/w drug: Florite® ratio). F-Co-adsorbate mixture of (1:3:5w/w drug: Tween 80: Florite® ratio).
2.1.2-Differential Scanning Calorimetric Studies
Differential scanning calorimetry (DSC) has been used for characterization of the state of the drug and studying its interaction with carriers (Signoretti, et al., 1986) . Figure ( 3) illustrates the thermograms of Celecoxib alone, Florite® alone its physical mixture, ground mixture, adsorbate and co-adsorbate with polysorbate 80 onto Florite®.
The DSC thermogram of Celecoxib (Trace F, Figure 3) shows a sharp endothermic peak at 160.37°C corresponding to its melting point of the drug with enthalpy change (ΔH) of -90.76 J/g. Trace E of Figure ( 3) represents the DSC thermogram of Florite® alone, which is characterized by absence of any peaks within the temperature range employed (30-200°C) . This could be attributed to the inorganic nature of Florite® (Shaker et al., 1992) .
In case of physical and ground mixtures of the drug with Florite®, the drug endothermic peak at 160.37ºC remained clearly detectable and maintained its shape with reduced intensity. This may be due to the dilution effect of the carrier in a ratio of (1:5 w/w drug: carrier). Figure ( 3) Trace C. shows the DSC thermogram of the adsorbate of Celecoxib onto Florite® at a ratio of (1:5 w/w drug: carrier). A very weak endothermic peak was observed for Celecoxib in its adsorbate, although the peak observed was a trace and the peak position was slightly shifted to lower temperature compared to the melting endothermic peak for pure drug. In general, the melting point of drug molecules in the pores is lower than that of bulk state (Etzler, 1987) . (Nakai, 1984) reported this phenomenon with porous silica or porous cellulose as carriers in the mixing system of drug crystals and the porous materials. Figure ( 3) Trace D, shows the coadsorbate of Celecoxib and polysorbate 80 onto Florite® at a ratio of 1:3:5 w/w drug: polysorbate 80: Florite®) polysorbate 80 being a liquid at the investigated temperature range, shows no significant peaks when adsorbed onto surface of Florite®.
800.0
DSC thermograms of the co-adsorbates of Celecoxib with polysorbate 80 onto Florite® in a (1:5:5 w/w ratio) show complete disappearance of the endothermic peak of the drug at 160.37ºC (Trace D, Figure 3) . The loss of crystallinity of Celecoxib in its coadsorbates with porous calcium silicate (Florite®) was explained in the view of the physical adsorption phenomena associated with drug silanol interaction within the inner pores of the silica matrix, adsorption may takes place via Van der Waal forces.
The DSC thermograms of co-adsorbate of Celecoxib with polysorbate 80 onto Florite® exhibited a complete disappearance of endothermic peak of the drug. Similar results were obtained by Hanawa et al., (1995) who reported that adsorption of ethenzamide onto porous calcium silicate (Florite®) resulted in conversion of the drug to the amorphous state with disappearance of drug characteristic peak. 
2.1.3-X-Ray Diffraction Studies
Powder X-ray diffraction technique has been utilized to study the crystallographic nature of the different prepared systems of the drug with Florite®. The X-ray diffraction patterns of Celecoxib, Florite® as well as their corresponding ground, adsorbate in a ratio of (1:5 w/w drug: carrier) and co-adsorbate of (1:3:5 w/w drug: Tween 80: Florite®) in comparison with the physical mixture at the same ratio, are presented in Figure (4) .
Celecoxib shows crystalline structure with sharp characteristic peaks, particularly at 2θ of 6.09º, 11.43º, 15.53º, 16.82º, 22.25º, 22.92º, 27.72º, 30.31º and 33.27º etc. (Figure 4 , Trace A). Florite® shows characteristic peaks at 2θ of 43.61º and 37.64º (Figure 4, Trace B) .
The crystallinity of Celecoxib in their physical and ground mixtures with Florite® remarkably decreased when compared with the pure drug. It may be attributed to dilution effect of Florite®, as also indicated in DSC studies.
Significant reduction in peak intensities of Celecoxib was observed in powder x-ray diffraction pattern of adsorbates of the drug with Florite® at a ratio of (1:5 w/w drug: carrier), probably of the rapid drying rate from methanol solution.
Co-adsorbate of Celecoxib with polysorbate 80 onto Florite® in a ratio of 1:3:5 w/w is shown in Figure 4 , Trace C. Co-adsorbates of the drug exhibited a completely halo patterns with no diffraction peaks derived from Celecoxib observed.
The X-ray diffraction data indicated that Florite® has a greater ability to induce the transformation of Celecoxib to amorphous state in its co-adsorbates (1:3:5 w/w drug: polysorbate 80: Florite® ratio) than that in their ground and physical mixtures with Florite® (1:5 w/w drug: Florite®). Therefore, both the amorphization and the decreased crystallinity of Celecoxib might be associated with hydrogen bonding between Celecoxib and the silanol group of Florite®. Similar results are obtained by Takeuchi 
2.2-In Vitro Dissolution Studies from Celecoxib Adsorbate and Co-adsorbate:
The effect of different ratios of Florite® or Aerosil 200 on the release behavior of Celecoxib from various systems prepared by different techniques is shown in Tables (7 & 8) . It is obvious that, the rate of Celecoxib dissolution varies with the nature of the material components and surface area, the ratio of drug to adsorbent, and the methods by which the loaded mixtures were prepared.
The dissolution rate of Celecoxib from various systems decreased in the following order: adsorbates > grinding systems > physical mixtures > pure drug. Physical and ground mixtures of Celecoxib with either Florite® or Aerosil 200 show slightly higher drug release than that drug alone. Increasing the concentration of the used carrier from the ratio of 1:1 to 1:5 w/w (drug: carrier) led to increase the dissolution rate of the drug from these prepared systems. It is found that the dissolution rate of Celecoxib solvent deposited onto Florite® is higher than those with Aerosil 200.
The adsorbates of Celecoxib with Florite® dissoluted 21.7% of the drug, while the corresponding adsorbates with Aerosil 200 released only 15.8% of the drug using the same ratio after the same time (Table 7 & 8) .
Silicates are of outstanding importance in pharmaceutical formulations as carriers in solid, semisolid and liquid dosage forms due to their excellent physicochemical properties. Florite® is porous calcium silicate. It has extensive surface area (140 m 2 /g), good flowability and excellent mouldability. Moreover, it is a pure synthetic inorganic unabsorbable material so that it is considered safe for oral administration. Molecular dispersions of drugs onto the extremely large surface of porous silica have been utilized for improving dissolution rates and absorption of several poor water soluble drugs.
It is clear that both solvent deposited systems and ground mixtures demonstrate a marked increase in the release rate of Celecoxib than that of physical mixtures or drug alone with either Florite® or Aerosil 200. The higher dissolution rate of Celecoxib in these prepared systems could be explained in view of rapid desorption of the physically adsorbed drug molecules when these mixtures are placed into the dissolution medium. Thus the drug molecules released simultaneously into the dissolution medium. The dissolution mechanism is therefore different from that of physical mixture where dissolution occurs from the surface of the drug crystals according to concentration gradient. The dissolution rates of Celecoxib from their co-adsorbate systems with polysorbate 80 onto surface of Florite® or Aerosil 200 are shown in Table ( 9) , and graphically represented by Figures (5 A&B) . The co-adsorbates were prepared by solvent deposition method using drugto-surfactant to adsorbent at ratios of (1:1:5, 1:3:5 and 1:5:5 w/w, respectively).
It is found that increasing the concentration of surfactant in the co-adsorbate results in obvious enhancement in drug dissolution rate. The possible explanation for this effect is that surfactants can be adsorbed on the surface of solid carriers leading to the formation of aggregates called "admicelles". These aggregates can incorporate hydrophobic drug molecules in their cores resulting in the phenomenon of ad-solubilization or co-adsorption (Cherkaoui et al., 2000) . Buckton et al., (1991) shown that the rate of drug release can be much increased by the presence of surfactants at the solid surfaces as a third component system. The increased wettability of the surface of the solid particles may also be an important parameter in drug release investigation.
Co-adsorbates prepared using Florite® as an adsorbent as a carrier show higher dissolution rates compared with those prepared using Aerosil 200. Co-adsorbate of the drug with Tween 80 onto Florite® released 100% of the drug after 30 min., while 19.93% drug released from co-adsorbate of the drug with Tween 80 onto Aerosil 200 after the same period.
This may reflect the highly porous structure and adsorption capacity of porous calcium silicate (Florite®) compared with silicon dioxide (Aerosil 200) (Hanawa et al., 1997). 
Celecoxib Co-adsorbate Floating Capsules
Floating capsules were formulated according to composition tabulated in table (2). Coadsorbate of Celecoxib with Florite ® and polysorbate 80 because the percentage of drug release obtained from this co-adsorbate was higher than Aerosil 200 and polysorbate 80 coadsorbate in the selected ratio. Table ( 10) showed the floating properties of Celecoxib capsule formulae (C1-C6) in pH 1.2 buffered solutions. The floating time is the time for the capsule to remain buoyant on the gastric fluid. All the prepared formulae of Celecoxib capsules immediately floated on the surface of the dissolution medium. After the hard gelatin gel dissolved, the contents of the capsule adhered together forming a single unit that continued to float and swell till the end of the time (8 hours). During this time, Celecoxib diffused through the co-adhered matrix to be released in the dissolution medium.
3.1-Floating Behavior of Celecoxib Co-adsorbate Floating Capsules
Hydroxypropyl methylcellulose (HPMC 4000 cps.) is responsible for the floating properties of the dosage forms. When come in contact with gastric fluid, it swells forming a hydrocolloid that has a bulk density lower than that of the gastric fluid and remains therefore buoyant on the stomach contents. Decreasing the concentration of HPMC 4000 from 50 mg in capsule (C5) to 25 mg in capsule (C1) led to a marked decrease in the floating time of the capsule from 8hrs to 5.30 hrs, (Table 10) .
Florite® (porous calcium silicate) has a characteristic porous structure and very low density. It has been used for the development of intragastric floating and sustained-release preparations. The floating ability of Florite® results from the air trapped in the porous structure of calcium silicate (Yuasa et al., 1996) . It was found that the preliminary adsorption of the drug to surface of Florite® resulted in enhancement of the floating properties of the capsules. These results are in agreement with Yuasa et al., (1996) who reported that the use of Florite® in the intragastric diclofenac sodium granules produced a prolonged floating time.
The prepared floating capsules (C5) showed the best floating behaviors followed by formula (C4) as illustrated in table (10) thus can be explained by the inclusion of highest amount of HPMC 4000 in capsule (C5) and highest ratio of florite in formula C4 and C5 (1:5) w/w drug Florite ®. 
Formula
Floating time Description C 1 5 hours and 30 minutes -The capsule first took its definite shape, then after the stated time, the contents of the capsule dispersed and some of the particles remained floating.
-The solution was quiet turbid.
C 2 6 hours -The hard gelatin capsule first took its definite shape, then after the stated time, the contents of the capsule dispersed and some of the particles remained floating.
-The solution was more turbid than that of C 1.
C 3 6 hours and 15 minutes -The hard gelatin capsule first took its definite shape, then after the stated time, the contents of the capsule dispersed and some of the particles remained floating.
-The solution was more turbid than that of C 2.
C 4 6 hours and 40 minutes -The hard gelatin capsule first took its definite shape, then after the stated time, the contents of the capsule dispersed and some of the particles remained floating.
-The solution was more turbid than that of C 3.
C 5 All the time (8 hours)
-The contents of the capsule did not rupture and retained its definite shape while floating absorption of water caused the capsule to increase in size and take the shape of a gelatinous mass structure.
-The solution was clear.
C 6 5 hours and 45 minutes -The hard gelatin capsule first took its definite shape, then after the stated time, the contents of the capsule dispersed and some of the particles remained floating.
-The solution was highly turbid. Table ( 11) and Figures (6 A&B) showed the dissolution behavior of Celecoxib from the prepared floating Celecoxib Co-adsorbate capsules (C1-C6) in 0.1 N HCl (pH 1.2). Coadsorbate of the drug with polysorbate 80 onto surface of Florite® were prepared by solvent deposition method, to enhance the solubility and dissolution of Celecoxib in gastric medium (pH 1.2). Thus, controlled release limited by drug dissolution was precluded and delivery of Celecoxib was controlled by the formulation.
3.2-In-Vitro Drug Release Study of the Prepared Floating Capsules of Celecoxib Coadsorbate
Figure (6 A) illustrates the effect of different ratios of co-adsorbate on Celecoxib release from formulae (C1-C4) containing the same amount of HPMC 4000 (25 mg) and anhydrous Lactose as a filler. The release of Celecoxib from its floating capsules containing different coadsorbate ratios was decreased in the following order: 1:5:3 > 1:3:5 > 1:2:3 > 1:1:1 w/w (drug: Florite®: polysorbate 80). The percentage released of Celecoxib from the best ratio of coadsorbate (1:5:3) reached nearly 96.63 % after 8 hours. The possible explanation for this effect is that surfactants are adsorbed on the surface of solid carriers leading to the formation of aggregates called "admicelles". These aggregates can incorporate hydrophobic drug molecules in their cores resulting in the phenomenon of adsolubilization or coadsorption (Cherkaoui et al., 2000) . Increased wettability of the surface of the solid carrier by the presence of surfactant molecules as a third component system was taken as an important parameter in drug release investigation (Buckton et al., 1991) .
Figure (6 B) shows the effect of different concentrations of HPMC 4000 on Celecoxib release from formulae (C4-C6) respectively containing the same ratio of coadsorbate (1:5:3 w/w of drug: Florite®: polysorbate 80) and anhydrous Lactose as a filler. Increasing the amount of HPMC from 12.5 to 50 mg in capsules (C6 to C5) led to a marked decrease in the percentage released of Celecoxib from 96.63% to 60.21%. The highest release rate of Celecoxib from formula (C6) containing 12.5 mg HPMC can be attributed to drug dissolution from coadsorbate particles uncovered with the polymer in this low concentration (Yuasa et al., 1996) . 
3.3-Investigation of Celecoxib Release Kinetics
The mechanism of the drug release from Co-adsorbate floating capsules was investigated as mentioned above. Table (12) show calculated correlation coefficient for the invitro release of Celecoxib Co-adsorbate floating capsules. There is no one definite kinetic model can express the release of the drug from the capsules, According to the obtained results, drug release from the capsules can be described by different kinetic models (zero, first or Higuchi diffusion model) through the highest calculated correlation coefficient. 
CONCLUSION
From the previous results, DSC and IR analysis proved that Celecoxib is compatible with HPMC 4000cps, NaCMC, sodium bicarbonate, anhydrous lactose, and magnesium stearate. Thus, these excipients can be used in the formulation of Celecoxib floating capsules. Co-adsorbate of Celecoxib with polysorbate 80 onto Florite® at the ratios of (1:3:5 w/w and 1:5:5 drug: Polysorbate 80: Florite®) gave the highest percentage of Celecoxib released (reached about 100% after 15 and 45 min.; respectively). Floating casuples containing this drug co-adsorbate in ratio of 1:5:3 w/w of drug: Florite®: polysorbate 80 showed the highest release rates of Celecoxib. Finally formula of Celecoxib floating capsule containing (coadsorbate in 1:5:3 w/w of drug: Florite®: polysorbate 80, 12.5 mg of HPMC 4000, 10.5 mg of sodium bicarbonate, 3.5 mg magnesium stearate and 98.5 mg of anhydrous lactose) is recommended. This formula gave the highest drug release (96.63%) and accepted floating time (around 6 hours).
